Management of Massive Splenomegaly with Cytopenia

Diagnostic Evaluation

The presence of massive splenomegaly (>10 cm below costal margin) with cytopenia requires specific investigations, including complete blood count with peripheral smear review, bone marrow aspiration and biopsy, flow cytometry, abdominal imaging, liver function tests, and HIV and HCV testing 1, 2, 3, 4, 5.
The American Society of Hematology recommends a diagnostic workup that includes bone marrow aspiration and biopsy with cytogenetic analysis, particularly in patients >60 years or those with constitutional symptoms 3, 4.

The European Society for Medical Oncology recommends JAK inhibitors (ruxolitinib) as first-line treatment for symptomatic splenomegaly in myeloproliferative neoplasms, achieving significant spleen volume reduction and symptom improvement 1, 2.
The National Comprehensive Cancer Network recommends hydroxyurea as an alternative to JAK inhibitors, achieving spleen volume reduction in approximately 40% of patients at doses of at least 2 g/day for 3 months 3, 7, 1, 2.
The American College of Physicians recommends supportive therapy with erythropoietic stimulating agents for severe anemia (Hb ≤10 g/dL with serum erythropoietin ≤500 mU/dL) in patients with myelodysplastic chronic myelomonocytic leukemia (MD-CMML) 3, 4.
The European Hematology Association recommends rituximab alone (375 mg/m² for 4-8 weekly doses) as first-line therapy for splenic marginal zone lymphoma (SMZL), producing high overall response rate (>80%) and complete response rate (>40%) with minimal toxicity 6.

The American Society of Hematology recommends initiating treatment for anemia in myelofibrosis when hemoglobin <10 g/dL using corticosteroids, androgens, erythropoiesis-stimulating agents, or immunomodulators (lenalidomide preferred if del(5q) present) 7.
The National Comprehensive Cancer Network recommends erythropoietic stimulating agents for patients with severe anemia in CMML (Hb ≤10 g/dL and serum erythropoietin ≤500 mU/dL) 3, 4.

The European Society for Medical Oncology recommends avoiding diagnostic splenectomy when less invasive methods (bone marrow biopsy, flow cytometry, imaging-guided biopsy) can establish diagnosis 7.
The American College of Surgeons recommends pre-splenectomy requirements, including good performance status, absence of disseminated intravascular coagulation, cytoreduction with platelet count maintained <400×10⁹/L, prophylactic anticoagulation, and experienced surgical team 7.
The American Society of Hematology recommends considering iron chelation therapy if ferritin exceeds 1,000 μg/L in patients with myeloproliferative disorders and iron overload 1.